Experimental Considerations in Headspace Gas Chromatography - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Experimental Considerations in Headspace Gas Chromatography
In this case study of amines, the authors discuss several parameters to be considered in developing a headspace GC method.


Pharmaceutical Technology
Volume 34, Issue 5, pp. 76-79

Methods and materials

Instrumentation and sample materials. A gas chromatograph (Agilent 6890, Santa Clara, CA) with a G1888 (Agilent) headspace autosampler and 20-mL sample vials were used for the experiments. The column used for these amine analyses was a Restek RTX-5 AMINE (Bellefonte, PA), 30 m x 530 µm x 5 µm film thickness. Triethylamine (TEA) was purchased from FisherScientific (Division of Thermo Fisher Scientific, Waltham, MA); DMSO, n-butylamine, and allylamine were purchased from Sigma-Aldrich (St. Louis, MO); Water (high-performance liquid chromatography grade) was purchased from J.T. Baker (Phillipsburg, NJ); and dimethylformamide (DMF) was purchased from EMD Science (Darmstadt, Germany).


Table I: Headspace parameters
Stock TEA samples were prepared by diluting 138 µL into 100 mL of diluent, where the diluent was different ratios of either DMSO:water or DMSO:0.01M sodium hydroxide (NaOH). Analysis samples were further diluted 1 mL into 100 mL with the appropriate diluent for the experiment. This dilution resulted in a final TEA concentration of 0.0100 mg/mL. Stock n-butylamine samples were prepared by diluting 213 µL into 250 mL of diluent, where the diluent was either water, 0.1M NaOH, or DMSO. Analysis samples were further diluted 1 mL into 25 mL with the appropriate diluent for the experiment (different ratios of DMSO:0.1M NaOH or water). This dilution resulted in a final n-butylamine concentration of 0.0252 mg/mL. Stock allylamine samples were prepared by diluting 300 µL into 100 mL of diluent, where the diluent was either 0.001M NaOH, 0.01M NaOH, DMF (or DMSO), or ratios of DMF (or DMSO):base. Analysis samples were further diluted 1 mL into 100 mL with the appropriate diluent for the experiment. This dilution resulted in a final allylamine concentration of 0.0228 mg/mL.


Figure 2
GC method for TEA and n-butylamine: Three minutes isothermal at 50 °C, followed by a programmed temperature ramp at 20 °C/min to 130 °C, a hold period for 2 min, followed by a programmed ramp at 20 °C/m into 170 °C, a hold period for 3 min, followed by a ramp at 30 °C/min to 240 °C, with a four-minute hold period at the end of the temperature ramp. The injector temperature was 200 °C, and the detector (i.e., FID) temperature was 300 °C with a constant column flow of 3.8 mL/min of helium.


Figure 3
GC method for allylamine: Eight minutes isothermal at 45°C, followed by a programmed temperature ramp at 40 °C/min to 240 °C, with a four-minute hold period at the end of the temperature ramp. The injector temperature was 180 °C, and the detector (i.e., FID) temperature was 300 °C with a constant column flow of 3.8 mL/min of helium. Headspace parameters are shown in Table I.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here